HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

date
10:23 19/11/2026
avatar
GMT Eight
IMPACT THERAP-B (07630) rose over 15% against the market trend. As of press time, it was up 11.85% at HK$9.295, with a turnover of HK$53.443 million.
IMPACT THERAP-B (07630) rose over 15% against the market trend. As of press time, it was up 11.85% at HK$9.295, with a turnover of HK$53.443 million. On the news front, on November 17, Impact Therapeutics announced that its independently developed innovative drug Senaparib (Paisuning, overseas trade name Sepalna) has officially received the final decision from the European Commission, approving it for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This approval was formally granted following the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Senaparib thus becomes the first China-developed PARP inhibitor approved in the EU for first-line maintenance treatment of advanced ovarian cancer in the all-comer population, marking another breakthrough for a domestically developed targeted innovative drug for ovarian cancer in the European market.